PharmaTher Holdings Ltd.
PHRRF · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | 0.12 | -0.03 | 0.01 |
| FCF Yield | -7.65% | -18.40% | -32.60% | -31.74% |
| EV / EBITDA | -9.78 | -5.59 | -1.01 | -0.48 |
| Quality | ||||
| ROIC | -156.50% | -130.26% | -73.10% | -31.76% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 1.13 | 0.50 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 65.64% | -8.86% | 7.86% | -482.50% |
| Safety | ||||
| Net Debt / EBITDA | 0.61 | 0.70 | 1.50 | 2.31 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -226,877.53 | -66,352.77 |